ResearcherThe University of Texas MD Anderson Cancer CenterNo recent work listed

Robert Alan Newman

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-5661-5846; OpenAlex author ID A5083929738. Sources: OpenAlex.

Their work

Papers: 4
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 10

Papers, trials and grants by year

2015: 2 papers · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: 1 paper

Papers 4

A Phase II, Single-Arm, Open-Label, Bayesian Adaptive Efficacy and Safety Study of PBI-05204 in Patients with Stage IV Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.1634/theoncologist.2020-0440 ↗
Pharmacokinetics in Mouse and Comparative Effects of Frondosides in Pancreatic Cancer. Co-author DOI 10.3390/md14060115 ↗
PBI-05204, a supercritical CO₂ extract of Nerium oleander, inhibits growth of human pancreatic cancer via targeting the PI3K/mTOR pathway. Co-author DOI 10.1007/s10637-014-0190-6 ↗
Response to: Does the Nerium oleander extract PBI-05204 have potential for pancreatic cancer? Co-author DOI 10.1007/s10637-015-0208-8 ↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Peiying Yang · 2 shared papers, 2015 · strength 0.15
- Paper Response to: Does the Nerium oleander extract PBI-05204 have potential for pancreatic cancer? DOI 10.1007/s10637-015-0208-8 ↗
- Paper PBI-05204, a supercritical CO₂ extract of Nerium oleander, inhibits growth of human pancreatic cancer via targeting the… DOI 10.1007/s10637-014-0190-6 ↗
Marc T Roth · 1 shared paper, 2020 · strength 0.11
- Paper A Phase II, Single-Arm, Open-Label, Bayesian Adaptive Efficacy and Safety Study of PBI-05204 in Patients with Stage IV … DOI 10.1634/theoncologist.2020-0440 ↗
Raymond Couric Wadlow · 1 shared paper, 2020 · strength 0.11
- Paper A Phase II, Single-Arm, Open-Label, Bayesian Adaptive Efficacy and Safety Study of PBI-05204 in Patients with Stage IV … DOI 10.1634/theoncologist.2020-0440 ↗
Dana Backlund Cardin · 1 shared paper, 2020 · strength 0.11
- Paper A Phase II, Single-Arm, Open-Label, Bayesian Adaptive Efficacy and Safety Study of PBI-05204 in Patients with Stage IV … DOI 10.1634/theoncologist.2020-0440 ↗
Jordan D. Berlin · 1 shared paper, 2020 · strength 0.11
- Paper A Phase II, Single-Arm, Open-Label, Bayesian Adaptive Efficacy and Safety Study of PBI-05204 in Patients with Stage IV … DOI 10.1634/theoncologist.2020-0440 ↗
Erkut Hasan Borazanci · 1 shared paper, 2020 · strength 0.11
- Paper A Phase II, Single-Arm, Open-Label, Bayesian Adaptive Efficacy and Safety Study of PBI-05204 in Patients with Stage IV … DOI 10.1634/theoncologist.2020-0440 ↗
Vincent J. Picozzi · 1 shared paper, 2020 · strength 0.11
- Paper A Phase II, Single-Arm, Open-Label, Bayesian Adaptive Efficacy and Safety Study of PBI-05204 in Patients with Stage IV … DOI 10.1634/theoncologist.2020-0440 ↗
J. Al Shemaili · 1 shared paper, 2016 · strength 0.06
- Paper Pharmacokinetics in Mouse and Comparative Effects of Frondosides in Pancreatic Cancer. DOI 10.3390/md14060115 ↗
Thomas Edward Adrian · 1 shared paper, 2016 · strength 0.06
- Paper Pharmacokinetics in Mouse and Comparative Effects of Frondosides in Pancreatic Cancer. DOI 10.3390/md14060115 ↗
Yong Pan · 1 shared paper, 2015 · strength 0.05
- Paper PBI-05204, a supercritical CO₂ extract of Nerium oleander, inhibits growth of human pancreatic cancer via targeting the… DOI 10.1007/s10637-014-0190-6 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.